on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies to Announce Q2 2024 Financial Results
DBV Technologies, a clinical-stage biopharmaceutical company, will release its second quarter 2024 financial results on July 30, 2024. The announcement will be followed by a conference call and live audio webcast at 5:30 p.m. ET to discuss the results and provide a business update.
Participants can join the call by dialing +1-877-346-6112 (U.S.) or +1-848-280-6350 (International) and asking to join the DBV Technologies call. The live webcast and a replay will be accessible in the Investors & Media section of the company's website.
DBV Technologies focuses on developing treatments for food allergies through its proprietary Viaskin platform, currently under clinical trials for peanut allergies in children. The company is based in Châtillon, France, and has operations in Warren, NJ.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news